East China Pharmaceuticals: Subsidiary's clinical trial application for injectable HDM2017 approved by the US FDA.

East China Pharmaceutical announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received notification from the US Food and Drug Administration (FDA) that the clinical trial application for the injectable drug HDM2017, submitted by Zhongmei Huadong, has been approved for Phase I clinical trials in the United States for the treatment of advanced malignant solid tumors.